📰 Nasdaq Cmpx News
Nasdaq Cmpx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Cmpx. Real-time updates on events, politics, business and more.
May 2, 2024
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and HilleVax (NASDAQ:HLVX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Institutional and Insider Ownership 68.4% of Compass Therapeutics […]
February 21, 2024
Foresite Capital Management V LLC cut its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 5.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,246,977 shares of the company’s stock after selling 77,094 shares during the period. Compass Therapeutics […]
February 21, 2024
Foresite Capital Management V LLC lowered its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 5.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,246,977 shares of the company’s stock after selling 77,094 shares during the quarter. […]
January 30, 2024
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) saw a significant drop in short interest in January. As of January 15th, there was short interest totalling 1,980,000 shares, a drop of 12.8% from the December 31st total of 2,270,000 shares. Based on an average trading volume of 511,500 shares, the short-interest ratio is currently 3.9 […]
December 19, 2023
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 2,670,000 shares, a decline of 10.1% from the November 15th total of 2,970,000 shares. Based on an average trading volume of 312,500 shares, […]
September 3, 2023
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and Genenta Science (NASDAQ:GNTA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation. Analyst Recommendations This is a breakdown of […]
August 30, 2023
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
June 3, 2023
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) has been given an average rating of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in […]
June 1, 2023
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company...
May 31, 2023
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 2,060,000 shares, a drop of 5.9% from the April 30th total of 2,190,000 shares. Approximately 3.1% of the company’s stock are sold short. Based […]